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Preamble
More than 83 million people live with cardiovascular (CV) disease in
the ESC member countries, with peripheral vascular diseases as the
most predominant condition (more than 35 million) followed by
ischaemic heart disease (>29 million), underlining the public health
burden of the former in our continent.1
The ESC collaborated with European Society of Vascular Surgery
(ESVS) to publish the most comprehensive guidelines document on
the management of peripheral arterial diseases (PADs), encompass-
ing all the peripheral territories.2 Compared to the 2011 version,
major changes regard risk stratification for patients with asympto-
matic carotid disease, and those with critical limb-threatening ischae-
mia (CLTI), and a new specific chapter on cardiac diseases in patients
with PADs. Any presentation of PADs is associated with a very high
risk for CV events, and all patients require best medical therapy for
secondary prevention. In this respect, the VIVA3 and COMPASS4 tri-
als are definitely the two seminal randomized controlled trials
(RCTs) of the year.
The VIVA trial demonstrated the interest of multiple vascular
screening to improve population longevity (Table 1).3 Over 50 000
Danish men were randomized to receive an invitation for vascular
screening or not. Vascular screening consisted of arm blood pressure
and ankle-brachial index (ABI) measurement, and abdominal aorta
ultrasound. Positive cases were invited to consult their general practi-
tioners, while large abdominal aorta aneurysm (AAA) were referred
to vascular surgeons. After 4.4 years, the mortality was significantly
lower in the screening group (Table 1). The number needed to screen
to prevent one death was 169, far below the one necessary for any
cancer screening.
The COMPASS trial randomized 27 395 patients either with coro-
nary artery disease (CAD) or PADs [lower-extremity artery disease
(LEAD) or carotid stenosis or prior carotid revascularization] to
three different antithrombotic strategies. In the pre-defined sub-anal-
ysis of patients with PADs, the results were consistent with those
obtained in the entire population (Table 1): the combination of rivar-
oxaban 2.5 mg b.i.d.þ aspirin 100 mg was associated with a significant
28% reduction of a combination of CV death, myocardial infarction,
or stroke and a 46% reduction of major adverse limb events (MALE),
including amputation, as compared to aspirin 100 mg.4 Bleeding
events were higher under the combination therapy, except for fatal
bleeding. The net benefit including ischaemic and major bleeding
events remained in favour of the combination strategy. The clinical
implication for the management of these patients needs further analy-
ses to select specific subgroups with an optimal benefit/risk ratio
(RR). Also, the external applicability of these results is important;
among REACH participants with LEAD, 68% were COMPASS-
compatible, fulfilling inclusion, and exclusion criteria.15 The main rea-
son for not being COMPASS-compatible was a high-bleeding risk.
Hence, the bleeding risk stratification is of paramount importance.
Other specific studies in lower-
extremity artery disease
The 2017 ESC guidelines1 emphasize the optimal management of risk
factors in patients with PADs. A new analysis of the FOURIER trial
underscored the importance of lowering LDL-cholesterol in patients
with LEAD, with significant benefits with evolocumab, a PCSK-9
inhibitor (Table 1).7 This new analysis in patients with LEAD showed
similar benefits in terms of CV events reduction, and a significant
reduction of MALE. This is the first trial showing the benefits of a
lipid-lowering drug to reduce MALE, including amputation.
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Many patients with LEAD are diabetic. Recently strikingly positive
results on the CV benefits of sodium glucose cotransporter 2-inhibi-
tors have been presented, although concerns were raised regarding
the increased risk of amputation (mostly minor) with canaglifozin.16
A new analysis of patients with LEAD enrolled in the EMPA-REG trial
confirmed the benefits of empagliflozin in terms of mortality and CV
events (Table 1), without any difference in amputation rates as com-
pared to placebo.6 The need for improved diabetes care was under-
lined by a recent registry on 15 332 CLTI patients (47% diabetic),
showing that in spite of a 60% higher risk of infection and 40% higher
amputation rate (both in-hospital and at 4-year follow-up), diabetic
patients were revascularized less often (46% vs. 54%, P< 0.001).17
In another review of 60 998 hospitalizations of patients undergoing
revascularization or amputation in the USA for CLTI, the 30-days
readmission rate was 20%, mainly due to infections, persistent CLTI
symptoms, cardiac conditions, and procedural complications.18
Regarding revascularization, the Iliac, Common and External Artery
Stent Trial (ICE) is the first RCT to compare balloon-expandable
(BES) vs. self-expandable stents (SES).8 Among 660 patients under-
going iliac stenting, 1-year binary restenosis was significantly lower
after SES as compared to BES (Table 1). Furthermore, freedom from
target lesion revascularization (TLR) was higher in the SES group,
with no difference in peri-procedural complications or functional
outcome. At the femoropopliteal level, new evidence regarding
device choice came from a network meta-analysis (6091 patients).19
Five endovascular strategies were compared: bare metal stent (BMS),
covered metal stent (CMS), drug-eluting stent (DES), drug-coated
balloon (DCB), and plain balloon angioplasty (PTA). Drug-coated
balloon, DES, and CMS offered a significant reduction in 1-year TLR
vs. PTA (68%, 58%, and 48%, respectively). Additionally, DCB signifi-
cantly reduced TLR also vs. BMS (53%), appearing the preferable
revascularization device. The advantages of DCB were confirmed in
ISAR-STATH, an RCT randomizing 155 patients to three different
strategies: DCBþ BMS, PTAþ BMS, or directional atherectomy.9
The primary endpoint was significantly lower for DCBþ BMS than
PTAþ BMS, as well as 2-year TLR (Table 1). Further evidence favour-
ing DCB over PTA comes from the ILLUMENATE pivotal10 and
ILLUMENATE EU11 which randomized 300 and 222 patients, respec-
tively, to DCB or PTA; primary patency was significantly higher for
DCB in both trials (Table 1).
Cardiac risk should be assessed in patients undergoing vascular
surgery.2 In a nationwide US registry of patients undergoing non-
cardiac surgery, peri-operative myocardial infarction occurred in 2%
of patients with vascular surgery, among the highest risks compared
to other types of non-cardiac intervention [odds ratio (OR) 1.56,
95% confidence interval (95% CI) 1.52–1.59].20 Through a
propensity-matched analysis, the registry suggests that invasive man-
agement of peri-operative myocardial infarction would improve out-
comes; this deserves a trial enrolling patients with PADs.
Carotid artery disease
Optimal medical management
Patients with asymptomatic carotid artery stenosis should benefit
from best medical therapy.1 This has recently been confirmed in 864
patients with 50–69% or 70–99% carotid artery stenosis.21
Altogether, 4929 carotid ultrasound studies were performed on
1439 carotid arteries over 6.5 years. Ischaemic stroke/transient ische-
mic attack (TIA) and carotid revascularization occurred in 12.2% and
progression of the stenosis in 21.5% of patients. The quality of risk
factors control were independent predictors for the stenosis pro-
gression or occurrence of stroke/TIA (Figure 1).21
Revascularization
A meta-analysis of five RCTs including 3019 asymptomatic patients
compared carotid artery stenting (CAS) to surgery (CEA).5 After
CAS, the risk of any peri-procedural stroke and non-disabling stroke
as well as the composite of any peri-procedural stroke or death was
increased with borderline statistical significance (Table 1). There was
a trend for less peri-procedural myocardial infarctions after CAS.
There was no significant difference regarding incident long-term
stroke between the two techniques.
Women are at increased risk of peri-operative stroke, but gender-
specific data are sparse. In the National Surgical Quality
Improvement Program database (5620 CEA and 141 CAS), the early
post-operative outcomes in women with symptomatic carotid artery
stenosis were compared. During the first 30 days, MACE occurred in
12.2% and 5.2%, respectively after CAS and CEA (P< 0.001).22 In a
propensity-matched analysis including 125 pairs, the 30-day incidence
of post-operative MACE in the CAS group was 11.2% vs. 4.0% after
CEA (OR 2.8; P= 0.04). This is in favour of CEA as the preferred
option in women.
Early revascularization after an ischaemic stroke/TIA is recom-
mended in case of carotid stenosis, but the influence of the timing on
revascularization techniques has been poorly studied. In a pooled
analysis of individual data of 4138 patients from four RCTs, the risk of
stroke or death after CAS was higher than after CEA in those treated
within 7 days (8.3% vs. 1.3%, RR 6.7; 95% CI 2.1–21.9, adjusted for
age, sex, and type of qualifying event).23 These results favour of CEA
in the early days after a neurologic ischaemic event.
In a German registry (2009–14), a total of 13 086 CAS procedures
were analysed.24 In-hospital stroke or death occurred in 2.4% (1.7%
in asymptomatic and 3.7% in symptomatic patients). The multivari-
able analysis showed the use of an embolic protection device was an
independent predictor of lower in-hospital rates of stroke or death
(adjusted RR 0.65; 95% CI 0.50–0.85), major stroke or death
(adjusted RR 0.60; 95% CI 0.43–0.84), and stroke (adjusted RR 0.57;
95% CI: 0.43–0.77). This supports the recent recommendations in
favour of embolic protection device during CAS.2
Current practice of carotid revascularization was evaluated in 12
countries.25 Among 58 607 treated cases, the largest national and
international variation was seen in indications: overall, about half of
the patients were asymptomatic (48%), but this varied from 0%
(Denmark) to 73% (Italy). National variation between centres was
even bigger and was the highest in Australia (0–72%), Hungary
(5–55%), and the USA (0–100%). The odds for revascularization for
asymptomatic carotid stenosis were much higher in countries where
fee per case is paid to the operator (OR 5.8, 95% CI 4.4–7.7). Among
asymptomatic patients CAS was used most often in Sweden (26%)
while some countries (Finland, Iceland) did not use CAS at all.
An international effort is necessary to homogenize guidelines and
practices globally.
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Thoracic aorta
Echocardiography remains the most frequent imaging method to
assess the proximal aorta. The diameter varies according to the car-
diac cycle, site, and mode of measurement as well as age and body
size. In the multicentre collaborative NORRE study including more
than 700 healthy individuals, the normal reference ranges for the
proximal aorta dimensions have been set.26
Two studies from the Multi-Ethnic Study of Atherosclerosis
reported on aortic calcification on computed tomography (CT): the
first assessed the ascending aorta calcium and showed that this condi-
tion is rare in general population (3.4%).27 The ascending aorta cal-
cium density was inversely correlated with CV events, even after
adjustments for risk factors and the coronary artery calcium. The sec-
ond study focused on those with coronary artery calcium score of
zero and found no additional prognostic information from ascending
aorta calcium.28 A magnetic resonance imaging study showed the
prognostic interest of the aortic arch pulse-wave velocity, a marker
of aortic stiffness, in middle-age (45–54 years) subjects, but not at
older ages.29
Regarding aortic events, so far only the aortic diameter is consid-
ered as a risk marker from imaging for aortic dissection. Two inde-
pendent case-control studies, comparing patients with type-B aortic
dissection (TB-AD) with controls, suggest that beyond the diameter,
the age-related elongation of the aortic arch is also associated with
increased risk of TB-AD.30,31
Abdominal aorta
After screening, small AAAs require follow-up of the diameter, typi-
cally assessed by 2D ultrasound (US). Using 3D-US for assessment of
AAA volume in 179 patients with small AAAs, it was found that 3D-
US was accurate in assessing both diameter and volume as compared
to CT.32 During follow-up, 40% patients classified as stable according
to the diameter actually presented a volume growth highlighting the
higher sensitivity of this new method.
Data from one of the most comprehensive and nationwide regis-
tries in Europe come from Finland, showing the improvement in the
prognosis of patients with unruptured and ruptured AAA during the
last 2 decades (Figure 2).33 The VascuNet network analysed differen-
ces in AAA interventional methods and outcomes in 83 253 patients
through 11 countries during the 2005–09 and 2010–13 periods.34
The proportion of octogenarians operated increased between the
two periods from 18.5% to 23.1% (P< 0.0001) and similarly the pro-
portion of patients treated with endovascular aneurysm repair
(EVAR) increased from 44.3% to 60.6% (P< 0.0001). Mortality for
EVAR decreased from 1.5% to 1.1% (P< 0.0001), but the outcome
worsened for open repair from 3.9% to 4.4% (P= 0.008).
In some countries, AAAs are repaired by EVAR at a lower diame-
ter than recommended in guidelines. Based on data from almost
40 000 Medicare patients undergoing EVAR from 2001 to 2008, ear-
lier AAA repair by 5 mm has major consequences, with 22% excess
EVAR procedures and 42% and 37% increase in open and endovascu-
lar re-interventions.35 The cost per saved AAA rupture was esti-
mated to be 1 million USD.
After EVAR lifelong surveillance is necessary and CT-angiography
has been the preferred modality, while ultrasound duplex scanning
(DUS) with and without contrast enhancement (CEUS) is an alterna-
tive. A Cochrane review of 42 studies36 concluded that both DUS
and CEUS a have high specificity for identification of endoleaks; how-
ever, CEUS is more sensitive and can be routinely used, with CT scan
only when endoleak is suspected.
Venous thromboembolism
After an acute episode of venous thromboembolism (VTE) anticoa-
gulation is indicated for at least 3 months.37 Optimal anticoagulation
duration, beyond the initial period remains uncertain. Prandoni et al.
showed that anticoagulation in patients with a first episode of proxi-
mal DVT, based on the assessment of residual vein thrombosis and
serial D-dimer, leads to an overall annual rate of recurrent
Figure 1 Neurologic ischaemic events and stenosis progression in patients with asymptomatic carotid stenosis according to the quality of risk
factors management. Adapted from Shah et al.21 BP, blood pressure; TIA, transient ischemic attack.
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VTE <5%.38 However, in men this strategy needs further assessment.
Several prediction rules are proposed to identify patients at high risk
of recurrence.39 The REVERSE II study prospectively validated the
‘men continue and HERDOO2’ clinical prediction rule.40 This allows
identifying low-risk women, following a first unprovoked VTE, who
can safely discontinue anticoagulation once the initial treatment is
completed (3.0% recurrence per patient-year in low-risk women).
No predictors for low risk of recurrence were found in men. The
decision on whether to discontinue anticoagulation should therefore
be individually tailored and balanced against bleeding risk.
Once the decision to extend anticoagulant treatment is taken,
common agreement is to continue with the initial compound. The lat-
est EINSTEIN-CHOICE trial12 showed that standard (20 mg o.d.)
and lower dose rivaroxaban (10 mg o.d.), significantly reduced the
risk of recurrence compared to aspirin, without significant increase in
bleeding rates (Table 1).
In patients with proximal DVT treated with DOACs, persistence
of residual vein thrombosis is likely to occur less frequently than in
patients treated with conventional anticoagulation. These results may
have implications for the prognosis of patients with DVT.41
According to current guidelines, adjuvant catheter-directed
thrombolysis may be considered in selected patients with acute ilio-
femoral DVT, if performed in experienced centres, to diminish risk of
post-thrombotic syndrome (PTS). However, the recently published
ATTRACT trial (692 patients) failed to show the additional interest
of catheter-directed thrombolysis to decrease the risk of PTS, but
did result in a higher risk of major bleeding.13 While the PTS severity
score was lower in the pharmacomechanical group, this did not affect
Figure 2 Management of abdominal aorta aneurysm in the nationwide registry in Finland, 2000–14. Adapted from Laine et al.33 AAA, abdominal
aorta aneurysm; EVAR, endovascular aneurysm repair.
....................................................................................................................................................................................................................
Table 2 Characteristics included in the risk prediction scores for cancer-related venous thromboembolism (VTE)
Khorana Vienna CATS PROTECHT CONKO
Very high-risk tumours (pancreatic or gastric cancer)a 2 2 2 2
High-risk tumours (lung, gynaecological, lymphoma, bladder, or testicular cancer) 1 1 1 1
Pre-chemotherapy haemoglobin <10 g/dL or use of erythropoietin stimulating agents 1 1 1 1
Pre-chemotherapy white blood cell count >11 x 109/L 1 1 1 1
Pre-chemotherapy platelet count >_350 x 109/L 1 1 1 1
Body mass index >35 kg/m2 1 1 1
D-dimer >1.44mg/mL 1
Soluble P-selectin >_53.1 ng/mL 1
World Health Organization (WHO) performance status >_2 1
Gemcitabine chemotherapy 1
Platinum-based chemotherapy 1
Cut-off for classification of high-risk patients (points) >_3 >_5 >_3 >_3
Numbers represent the value attributed to each characteristic in the scores.
aThe Vienna CATS also included brain cancer as a high-risk site.
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..improve the quality of life of the patients. There was no difference
according to the site of DVT (57% had ilio-femoral DVT). The overall
results are in contradiction with a smaller trial reported previously in
favour of pharmacomechanical intervention, with decreased risk of
PTS after 5 years of follow-up.42 Further trials, focused on ilio-
femoral DVT, are required.
The clinical usefulness of VTE risk prediction scores in ambulatory
cancer patients is debated. A cohort of 876 cancer patients com-
pared several scores (Table 2).43 All models performed poorly (c-sta-
tistics: 0.50–0.57), indicating the need for improvements before these
models can be considered in clinical practice. Identifying predictors
for VTE recurrence in cancer patients remains a challenge. In two
cohorts of patients with cancer-associated VTE, the modified Ottawa
score showed modest discriminating power and was unable to pre-
dict the risk of VTE recurrences.44,45
Diagnostic algorithms are frequently used to identify patients in
whom pulmonary embolism (PE) can be ruled out without the use of
computed tomography pulmonary angiography (CTPA). In a study of
3465 patients with suspected PE, the YEARS decision rule (based on
three clinical items combined with two D-dimer cut-offs) yielded a
14% decrease in CTPA examinations compared to conventional
strategies (Figure 3) with a negative predictive value of 99.4%.46
Whether negative CTPA is sufficient to exclude PE in patients with
likely pretest probability is debated. Pulmonary embolism was
excluded with CTPA in 37% of patients with likely clinical probability,
and the 3-month VTE risk was 0.6%, indicating that a negative CTPA
safely excludes PE in this patient group.47
The prevalence of PE in patients presenting with syncope has been
highly debated this year, following the PESIT trial, reported last
year,39 describing a 17% rate of PE in syncope cases referred to
emergency rooms, after excluding cases with evident aetiology. A
meta-analysis including 6608 emergency department patients and
975 patients hospitalized for syncope reported a PE prevalence
<1%.48 Two other studies reported a PE prevalence of 1.4% among
patients with syncope.14,49 Routine screening for PE in all patients
presenting with syncope may not be justified.
The PEITHO trial investigated long-term prognosis in patients with
intermediate-risk PE randomized to receive thrombolysis or pla-
cebo.50 Thrombolytic treatment did not decrease long-term mortal-
ity rates, persisting dyspnoea, chronic thromboembolic pulmonary
hypertension, or right ventricular dysfunction.
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